Bank of America’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.07M | Buy |
874,397
+156,483
| +22% | +$1.04M | ﹤0.01% | 3455 |
|
|
2025
Q4 | $5.64M | Sell |
717,914
-876,952
| -55% | -$6.9M | ﹤0.01% | 3294 |
|
|
2025
Q3 | $13M | Sell |
1,594,866
-68,624
| -4% | -$456K | ﹤0.01% | 3038 |
|
|
2025
Q2 | $7.77M | Sell |
1,663,490
-45,919
| -3% | -$210K | ﹤0.01% | 3451 |
|
|
2025
Q1 | $9.38M | Buy |
1,709,409
+717,752
| +72% | +$2.9M | ﹤0.01% | 3204 |
|
|
2024
Q4 | $3.36M | Sell |
991,657
-17,544
| -2% | -$56.4K | ﹤0.01% | 3978 |
|
|
2024
Q3 | $2.88M | Buy |
1,009,201
+367,535
| +57% | +$944K | ﹤0.01% | 4243 |
|
|
2024
Q2 | $1.44M | Buy |
641,666
+13,619
| +2% | +$27.4K | ﹤0.01% | 4667 |
|
|
2024
Q1 | $1.39M | Buy |
628,047
+367,668
| +141% | +$951K | ﹤0.01% | 4711 |
|
|
2023
Q4 | $612K | Buy |
260,379
+190,592
| +273% | +$352K | ﹤0.01% | 5354 |
|
|
2023
Q3 | $130K | Buy |
69,787
+57,418
| +464% | +$132K | ﹤0.01% | 6127 |
|
|
2023
Q2 | $32.4K | Sell |
12,369
-35,217
| -74% | -$89.7K | ﹤0.01% | 6593 |
|
|
2023
Q1 | $77.6K | Sell |
47,586
-46,411
| -49% | -$58.1K | ﹤0.01% | 6348 |
|
|
2022
Q4 | $125K | Buy |
93,997
+18,058
| +24% | +$25.5K | ﹤0.01% | 6143 |
|
|
2022
Q3 | $119K | Sell |
75,939
-35,532
| -32% | -$58.8K | ﹤0.01% | 6265 |
|
|
2022
Q2 | $172K | Buy |
111,471
+64,630
| +138% | +$136K | ﹤0.01% | 6193 |
|
|
2022
Q1 | $120K | Buy |
46,841
+17,133
| +58% | +$41.9K | ﹤0.01% | 6765 |
|
|
2021
Q4 | $87K | Buy |
29,708
+15,284
| +106% | +$33K | ﹤0.01% | 6943 |
|
|
2021
Q3 | $35K | Sell |
14,424
-39,691
| -73% | -$115K | ﹤0.01% | 7203 |
|
|
2021
Q2 | $220K | Buy |
54,115
+26,666
| +97% | +$102K | ﹤0.01% | 6030 |
|
|
2021
Q1 | $124K | Buy |
27,449
+15,634
| +132% | +$84.3K | ﹤0.01% | 6300 |
|
|
2020
Q4 | $58K | Sell |
11,815
-89,684
| -88% | -$449K | ﹤0.01% | 6266 |
|
|
2020
Q3 | $602K | Buy |
101,499
+86,000
| +555% | +$344K | ﹤0.01% | 4572 |
|
|
2020
Q2 | $41K | Buy |
15,499
+8,604
| +125% | +$30K | ﹤0.01% | 6067 |
|
|
2020
Q1 | $13K | Sell |
6,895
-422
| -6% | -$1.81K | ﹤0.01% | 6294 |
|
|
2019
Q4 | $52K | Sell |
7,317
-2,929
| -29% | -$24.2K | ﹤0.01% | 6248 |
|
|
2019
Q3 | $101K | Buy |
10,246
+4,298
| +72% | +$48.3K | ﹤0.01% | 6047 |
|
|
2019
Q2 | $68K | Sell |
5,948
-12,315
| -67% | -$129K | ﹤0.01% | 6177 |
|
|
2019
Q1 | $184K | Buy |
18,263
+13,209
| +261% | +$169K | ﹤0.01% | 5566 |
|
|
2018
Q4 | $86K | Buy |
5,054
+4,090
| +424% | +$82K | ﹤0.01% | 5995 |
|
|
2018
Q3 | $17K | Buy |
+964
| New | +$20.9K | ﹤0.01% | 6545 |
|
Other funds holding XERS
VCM
RA
N
VPM
Bank of America's XERS Position: Q1 2026 in Review
Bank of America increased its Xeris Biopharma Holdings (XERS) stake by 22% in Q1 2026, buying an estimated $1.04M and bringing the position to 874,397 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3455.
Bank of America first reported a position in XERS in Q3 2018 and has held it in 31 quarters since. The position peaked at $13M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.
- Bank of America held 874,397 shares of Xeris Biopharma Holdings worth $5.07M as of Q1 2026.
- Bank of America bought 156,483 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.04M.
- Xeris Biopharma Holdings made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3455 holding.
- Bank of America first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 31 quarters since.
- Bank of America's Xeris Biopharma Holdings position peaked at $13M in Q3 2025.
- 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.